Have a feature idea you'd love to see implemented?
Let us know!
VYNE VYNE Therapeutics Inc
Price (delayed)
$3.23
Market cap
$47.65M
P/E Ratio
0.96
Dividend/share
N/A
EPS
$3.38
Enterprise value
$31.45M
VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Highlights
VYNE's EPS has soared by 134% YoY and by 104% QoQ
VYNE's gross profit is up by 39% YoY
VYNE Therapeutics's quick ratio has surged by 127% YoY but it has decreased by 17% QoQ
The net income has decreased by 20% from the previous quarter and by 6% YoY
VYNE's equity is down by 15% since the previous quarter
Key stats
What are the main financial stats of VYNE
Market
Valuations
Earnings
Shares outstanding
14.75M
Market cap
$47.65M
Enterprise value
$31.45M
Price to earnings (P/E)
0.96
Price to book (P/B)
0.75
Price to sales (P/S)
279.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
63.8
Revenue
$493,000
Gross profit
$493,000
Net income
-$34M
EBIT
-$34M
EBITDA
-$34M
Free cash flow
-$30.11M
Per share
Balance sheet
Liquidity
EPS
$3.38
EPS diluted
$3.38
Free cash flow per share
-$0.71
Book value per share
$4.31
Revenue per share
$0.01
TBVPS
$1.79
Total assets
$76.2M
Total liabilities
$12.66M
Debt
$123,000
Equity
$63.54M
Working capital
$60.87M
Debt to equity
0
Current ratio
5.81
Quick ratio
5.55
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
-6,896.6%
Gross margin
100%
Net margin
-6,896.6%
Operating margin
-7,646.9%
Return on assets
-38.6%
Return on equity
-43.8%
Return on invested capital
-62.3%
Return on capital employed
-53.5%
Return on sales
-6,896.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYNE stock price
How has the VYNE Therapeutics stock price performed over time
Intraday
8.75%
1 week
35.15%
1 month
11.76%
1 year
28.69%
YTD
38.63%
QTD
71.81%
Financial performance
How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$493,000
Gross profit
$493,000
Operating income
-$37.7M
Net income
-$34M
Gross margin
100%
Net margin
-6,896.6%
VYNE's gross profit is up by 39% YoY
The revenue is up by 39% year-on-year
VYNE Therapeutics's operating income has decreased by 24% YoY and by 22% from the previous quarter
VYNE's net margin is up by 24% year-on-year but it is down by 18% since the previous quarter
Growth
What is VYNE Therapeutics's growth rate over time
Valuation
What is VYNE Therapeutics stock price valuation
P/E
0.96
P/B
0.75
P/S
279.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
63.8
VYNE's EPS has soared by 134% YoY and by 104% QoQ
VYNE's P/B is 73% above its last 4 quarters average of 0.4 but 64% below its 5-year quarterly average of 1.9
VYNE's equity is down by 15% since the previous quarter
VYNE's P/S is 47% above its last 4 quarters average of 175.1
The revenue is up by 39% year-on-year
Efficiency
How efficient is VYNE Therapeutics business performance
The ROE has soared by 71% YoY
The ROA has soared by 64% YoY
VYNE's ROS is up by 24% YoY but it is down by 18% QoQ
VYNE's return on invested capital is up by 8% since the previous quarter
Dividends
What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYNE.
Financial health
How did VYNE Therapeutics financials performed over time
VYNE Therapeutics's quick ratio has surged by 127% YoY but it has decreased by 17% QoQ
The current ratio has surged by 114% year-on-year but it has declined by 19% since the previous quarter
VYNE's debt is 100% smaller than its equity
VYNE's debt is down by 15% since the previous quarter
VYNE's equity is down by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.